Photo by impulsq from unsplash
UroVysion in Fluorescence in situ Hybridization, urine miRNA and urine cell-free DNA show high clinical application value for the diagnosis of BLCA. Xu et al. developed a novel urine cytology… Click to show full abstract
UroVysion in Fluorescence in situ Hybridization, urine miRNA and urine cell-free DNA show high clinical application value for the diagnosis of BLCA. Xu et al. developed a novel urine cytology test (UCT) by mixing urine with mNPs (Nano-cytology) to harvest more tumor cells during UCT procedures. The Nano-cytology assay had a signi fi cantly improved sensitivity compared with UCT for detecting BLCA patients. It represents a promising tool for diagnosis of BLCA in clinical practice. Ye et al. utilized non-negative matrix factorization (NMF)
Journal Title: Frontiers in Cell and Developmental Biology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!